Partnerships Picks For GeNeuro’s MS Antibody
GeNeuro’s CEO And His Mission To Bring Anti-HERV Benefits To MS Patients
Executive Summary
The Geneva-based biotech has been developing its antibody temelimab for the last 16 years. Data from its Phase II studies show its need for a big pharma development partner.